GlassScriptPhysician profile
Steven C Lewis
NPI 1427005735
$3,497.35
in general payments reported to CMS, 2019-2025
40 companies · $853 in 2025
The $853 reported for 2025 was more than what 88% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $435 · 2021: $417 · 2022: $388 · 2023: $428 · 2024: $541 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.56 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $272.57 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $237.04 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $234.88 | 2020-2025 | Austedo Xr, Austedo Xr |
| Acadia Pharmaceuticals INC | $189.55 | 2019-2025 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $178.66 | 2020-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $151.09 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Bayer Healthcare Pharmaceuticals INC. | $142.27 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $126.73 | 2023 | Aptiom, Gemtesa |
| Sun Pharmaceutical Industries INC. | $125.28 | 2020-2022 | |
| Insmed, INC. | $106.47 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $106.45 | 2022-2025 | Rexulti, Nuedexta |
| Eisai INC. | $106.07 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $104.16 | 2023-2025 | Ingrezza |
| Pfizer INC. | $102.78 | 2022-2025 | |
| Gilead Sciences, INC. | $97.56 | 2024-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $96.30 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.14 | 2020-2024 | Jardiance, Spiriva Respimat |
| Alpha Cognition USA, INC. | $80.78 | 2025 | Zunveyl |
| Lilly USA, LLC | $76.99 | 2022-2023 | Amyvid, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $74.52 | 2019-2020 | |
| Lundbeck LLC | $72.19 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $69.93 | 2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.28 | 2020-2021 | |
| Urovant Sciences INC | $54.61 | 2022 | |
| Xeris Pharmaceuticals, INC. | $50.70 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $50.10 | 2021-2022 | |
| Verona Pharma, INC. | $48.50 | 2025 | Ohtuvayre |
| Vanda Pharmaceuticals INC. | $46.75 | 2020-2021 | |
| Ucb, INC. | $45.19 | 2023 | Nayzilam |
| Biogen, INC. | $42.92 | 2024 | Spinraza, Skyclarys |
| Lexicon Pharmaceuticals, INC. | $37.81 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $33.41 | 2024 | Dificid |
| Astellas Pharma US INC | $28.97 | 2020-2021 | |
| Dexcom, INC. | $28.90 | 2025 | Dexcom G6 Transmitter |
| Sk Life Science, INC. | $28.90 | 2025 | |
| Amgen INC. | $24.08 | 2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $22.23 | 2025 | Cobenfy |
| Amarin Pharma, INC. | $18.78 | 2020 | |
| Scilex Pharmaceuticals INC. | $16.90 | 2022 | |
| Abbott Laboratories | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.